Phase II Study of the Efficacy of the Pneumococcal Pneumonia Vaccine Series in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency (PROTECT CLL)
Latest Information Update: 22 Apr 2026
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 23-valent vaccine Walvax Biotechnology (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms PROTECT CLL
Most Recent Events
- 09 Apr 2026 Planned number of patients changed from 60 to 61.
- 09 Apr 2026 Planned primary completion date changed from 1 Jun 2026 to 1 Mar 2027.
- 17 Feb 2026 Planned End Date changed from 7 Jan 2028 to 1 Jun 2028.